Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Soaring Today

By Keith Speights - Updated May 18, 2020 at 10:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about promising early data from a study of the biotech's novel coronavirus vaccine.

What happened

Shares of Moderna (MRNA 1.83%) were soaring 24.1% higher as of 10:13 a.m. EDT. The big jump came after the biotech announced positive interim data from a phase 1 clinical study of novel coronavirus vaccine candidate mRNA-1273. 

So what

People across the world are anxiously awaiting good news from the race to develop a COVID-19 vaccine. Moderna's results were admittedly early, but the company's news was certainly good.

Gloved hand holding syringe with Covid-19 vaccination printed on it

Image source: Getty Images.

After two doses, all participants receiving the 25 microgram and 100 microgram doses of mRNA-1273 had levels of antibodies that bind to the novel coronavirus that were similar to or higher than levels seen in patients who have recovered from COVID-19. Eight participants who received either the 25 microgram or 100 microgram dose of mRNA-1273 had levels of neutralizing antibodies, which defend against infection by the novel coronavirus, at day 43 of the study at similar or higher levels than those seen in patients who have recovered from COVID-19.

Moderna said that mRNA-1273 appeared to be generally safe and well tolerated. The company stated that the most significant adverse events occurred at the highest dose level (250 micrograms). However, it noted that all adverse events were only temporary and resolved themselves.

Now what

Based on the interim data from the early stage study of mRNA-1273, which is being led by the National Institute of Allergy and Infectious Diseases (NIAID), a 50 microgram dose level cohort will be added to the study. Moderna also plans to add a 100 microgram dose to the phase 2 study it is conducting.

The company hopes to start a phase 3 study of mRNA-1273 in July. If the results from that study are positive, Moderna plans to quickly file for regulatory approval of its COVID-19 vaccine. Today's jump for the biotech stock would likely be small in comparison to what would happen if Moderna's messenger RNA vaccine is successful in late-stage testing.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$174.27 (1.83%) $3.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.